5 mins ago – 11.51AMNeuren shares hit by short report, shares haltedTom RichardsonShare postNeuren shares are down 13 per cent this morning after a US short seller named Culper Research claimed its licensing partner Acadia has misrepresented the safety profile of a drug named Daybue to treat Rett syndrome, which Neuren licenses to Acadia. The short seller also claimed the estimates of sell side analysts for Daybue sales are too high and that sales peaked in August 2023. Neuren has not immediately responded to a request for comment. Its shares have rocketed 1516 per cent over the past five years thanks to the successful commercialisation of Daybue and licensing agreement with Acadia.
came on AFR.
Ann: Pause in Trading, page-22
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B | |||
| Open | High | Low | Value | Volume |
| $14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $13.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.07 | 6644 | 4 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |